Solvonis Therapeutics PLC

1. 06 Oct 26
   Investor Webinar – 15 October 2026

   Building a leader in addiction and mental health therapeutics

   RNS 9807697 ↗
2. 30 Sep 26
   Notification of Admission of Shares and TVR

   LONDON - 30 September 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces that further to the...

   RNS 9799223 ↗
3. 30 Sep 26
   Unaudited interim results

   Unaudited interim results for the six months to 30 June 2026

   RNS 9799218 ↗
4. 29 Sep 26
   New Analysis Identifies Major AUD Breakthrough

   New Analysis Identifies Major AUD Breakthrough: SVN-001 Ahead of Established and Emerging AUD Treatments in Cross-Trial Analysis

   RNS 9795238 ↗
5. 03 Sep 26
   Vital Patent milestone achieved– SVN 114

   Composition-of-matter allowance strengthens proprietary position in a large and increasingly strategic PTSD market

   RNS 9752834 ↗
6. 25 Aug 26
   Solvonis Raises £1.3 Million

   Solvonis Raises £1.3 Million to Advance Key Clinical and Regulatory Milestones

   RNS 9737672 ↗
7. 11 Aug 26
   Solvonis to Present at WTR Conference

   Solvonis to Present at WTR Virtual Insights Conference

   RNS 9714402 ↗
8. 06 Aug 26
   SVN-015 Advances into Further NIDA-Funded Studies

   SVN-015 Advances into Further NIDA-Funded Studies Following Encouraging Initial Screening

   RNS 9707238 ↗
9. 13 Jul 26
   Research Coverage Initiation

   Water Tower Research Initiates Coverage, Highlighting Significant AUD Market and Valuation Opportunity

   RNS 9665208 ↗
10. 22 Jun 26
    Announces Positive Bridging Data Supporting

    PK Data Support Scientific Bridge to Approved Intranasal Esketamine Reference Product

    RNS 9628647 ↗
11. 19 Jun 26
    Result of AGM

    LONDON - June 19, 2026 - Solvonis Therapeutics plc (LSE: SVNS) ("Solvonis" or the "Company"), a late clinical stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces...

    RNS 9627673 ↗
12. 27 May 26
    Notice of AGM

    RNS 9587915 ↗
13. 05 May 26
    CSO Speaks at National Research Meeting

    Solvonis Chief Scientific Officer Professor David Nutt to Speak at U.S.

    RNS 9551033 ↗
14. 29 Apr 26
    Final Results

    FY2025 transformation complete as Board refines strategy around the SVN-001 Phase 3 value inflection point

    RNS 9542766 ↗
15. 22 Apr 26
    Appointment of Water Tower Research

    Appoints Water Tower Research to deepen U.S. market understanding, refine Company profile and expand institutional investor reach

    RNS 9531563 ↗
16. 20 Apr 26
    US CNS Executive Order

    Welcomes President Trump's Executive Order as a positive signal for rapid-acting CNS therapies in the United States

    RNS 9527980 ↗
17. 08 Apr 26
    Granted U.S. Patent from PTSD Discovery Programme

    Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces that it has been granted a second U.S. patent by the United States...

    RNS 9509194 ↗
18. 31 Mar 26
    Granted U.S. Patent from PTSD Discovery Programme

    Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces it has been granted a U.S. patent by the United States Patent and...

    RNS 9499262 ↗
19. 10 Mar 26
    SVN-114 selected for PTSD discovery programme

    SVN-114 selected as the lead candidate for PTSD discovery programme

    RNS 9465849 ↗
20. 28 Jan 26
    Expansion of SVN-015 into depression

    Expansion of SVN-015 into depression following positive preclinical data

    RNS 9390351 ↗
21. 07 Jan 26
    US Patent allowance for PTSD discovery programme

    Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces that it has received a Notice of Allowance (the "Allowance") from the United States...

    RNS 9337656 ↗
22. 22 Dec 25
    Research and Development Update – Q4 2025

    Pipeline advancing across addiction and psychiatry with multiple 2026 catalysts

    RNS 9311270 ↗
23. 03 Dec 25
    SVN-015 accepted into US NIDA funded programme

    Solvonis' Novel Compound SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction

    RNS 9271973 ↗
24. 31 Oct 25
    Total Voting Rights

    RNS 9207049 ↗
25. 31 Oct 25
    Corporate Structure Update and Issue of Options

    Corporate Structure Update, Disposal of Non-Core Subsidiary, and Issue of Options

    RNS 9205070 ↗
26. 27 Oct 25
    Appoints global biopharma leader Paul Carter

    Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

    RNS 9195094 ↗
27. 16 Oct 25
    Raises £1.25 Million to Accelerate Programmes

    Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

    RNS 9174045 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.